Stem Cells & Regenerative Medicine

30 March -1 April 2020 | Business Design Centre London

 

 

2000+
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
12
Streams

 

 

Stem Cells & Regenerative Medicine

STEM CELLS & REGEN MED, Tuesday 31 March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

08:45

Welcome – Jessica Robinson, Project Director, Advanced Therapies 2020, Terrapinn

Prasad Adusumilli
09:00

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion
Bradley Campbell
10:00

Importance of patient focus in developing gene therapy for rare diseases

10:20

Morning Coffee Break

Martin Pule
11:20

Keynote presentation: War in the Blood - the latest in the front line of CAR-T clinical research

Mark Sawicki
11:40

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables
12:00

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

10. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

16. Industrialisation of ATMPs
Mark Lowdell

Mark Lowdell, Chief Scientific Officer, Inmunebio

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, BOKU

21. Neurological applications for ATMPs
John Isaac

John Isaac, Senior Director, External Scientific Innovation And Neuroscience, Johnson & Johnson

22. Development of regenerative medicines for cardiovascular indications
David Mazzo

David Mazzo, Chief Executive Officer, Caladrius Biosciences

3. Ensuring safe delivery to patients and fast time-to-market of advanced therapies - How to address challenges of drug administration, fill & finish, packaging & stability?
Diana Lober

Diana Lober, Product Manager, Schott AG

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

7. Reserved for Fujifilm Diosynth Biotechnology
13:00

Lunch

STEM CELLS & REGEN MED

From clinic to commercialisation

Chaim Lebovits
STEM CELLS & REGEN MED
14:20

Stem Cells for neurological applications, Clinical and stem cells-based product development

Johannes De Munter
STEM CELLS & REGEN MED
14:40

Industrialized personalized regenerative medicine, promising but very challenging

  • ATMPs in personalized regenerative medicine
  • GMP and remote manufacturing as part of GMP-ATMP and one batch-one patient strategy
  • Safety and autologous stem cell products and regulatory hurdles
Bill Tente
STEM CELLS & REGEN MED
15:00

Ground-breaking innovation in regenerative medicine; the development of the world’s first bioengineered blood vessel

Joe Dupere
STEM CELLS & REGEN MED
15:20

The use of cell therapies in regenerative medicine

Dr Michael West
STEM CELLS & REGEN MED
15:40

Using regenerative medicine to stop aging

Robert Deans
STEM CELLS & REGEN MED
16:00

Exploring the rise of machine learning and AI in next generation bioprocesses: Single Cell RNA sequencing to drive innovation and quality in iPSC therapeutics

Robert Deans, CSO, Synthego Corporation
16:20

Afternoon Break

Douglas Losordo
STEM CELLS & REGEN MED
17:00

Repair of the microcirculation reverses ischemic tissue damage

Peter Hamley
STEM CELLS & REGEN MED
17:20

Longevity and new approaches to diseases of ageing

Tongri Liu
STEM CELLS & REGEN MED
17:40

In Pursuit of the First Clinical Trial for a Chinese iPSc Derived ATMP (iPSc-Endothelial Progenitor Cell) in the UK

  • Manufacturing protocols and QC standards for iPSc-EPC have been developed in Allife Medicine.
  • Pre-clinical studies have shown positive effects on neuron re-myelination in rats and that iPSc-EPC is able to trigger endothelium lesion recovery in nude mice, with little safety concern in Toxicity and Tumorigenesis.
  • A Phase I/IIα clinical trial to use autologous iPSc-EPC for Ischemic Stroke is planned to start in early 2021.
18:00

Close of Conference for the day - Please join us for an evening drinks reception

last published: 04/Jun/20 09:25

STEM CELLS & REGEN MED, Wednesday 1 April 2020

CONFERENCE DAY 1 - WEDNESDAY 1st April 2020

Opening Keynotes Day 2 — The latest science in gene therapy and gene editing

Federico Mingozzi
09:00

Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies

  • Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
  • Tackling the challenges of viral gene therapies i.e. immunogenicity
  • Developing the next generation of gene therapies, what does the future hold?
Steve Kanner
09:20

Next-generation gene editing technology for allogeneic immune cell therapeutics

  • Next-generation CRISPR-Cas9 technology
  • Significantly enhanced editing specificity
  • Editing in immune cells for generation of functionally tuned therapeutics
Amy Pooler, Director, Neuroscience, Sangamo Theraputics
09:40

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
Frederic Chereau
10:00

In vivo gene editing paediatric patients with rare diseases

10:20

Networking Refreshments

STEM CELLS & REGEN MED

Chair: Stephen Badylak, Professor, Department of Surgery, Director, McGowan Center for Pre-Clinical Studies, Deputy Director, McGowan Institute for Regenerative Medicine (MIRM)

Chirag Desai
STEM CELLS & REGEN MED
11:20

Challenges and Troubleshooting of starting auto-islet cell transplant program

  • Institutional, Financial and administrative challenges
  • Clinical challenges with different providers and patients
  • Different options and broad cost analysis of putting together facility and islet isolation team
Chirag Desai, Professor Of Surgery, Director, Chronic Pancreatitis And Autologous-Islet Cell Transplant Program, University of Pennsylvania School Of Medicine
Cornelia Kasper
STEM CELLS & REGEN MED
11:40

Cultivation strategies for stem cell expansion and cell-based therapy products

Cecilia Gotherstrom
STEM CELLS & REGEN MED
12:00

BOOSTB4 project and trial: using stem cells to tackle osteogenesis imperfecta

Frank Luyten
STEM CELLS & REGEN MED
12:20

Clinical translation in regenerative medicine

  • Define the Patient and its relevant Preclinical Development Path
  • Characterization and Production of Cell based products for Regenerative Medicine
  • Reimbursement and cost-effectiveness, willingness to pay
Sean Palecek
STEM CELLS & REGEN MED
12:40

Discovery of metabolic critical quality attributes for pluripotent stem cell-derived cardiomyocytes

  • Defined scalable processes for manufacturing cardiomyocytes from human pluripotent stem cells have been developed, but monitoring cell quality during manufacturing is challenging.
  • Profiling intracellular metabolites during cardiomyocyte differentiation and maturation has identified quality attributes related to cardiomyocyte state.
  • Monitoring medium composition during cardiomyocyte differentiation can predict successful and failed batches.
13:00

Neworking Lunch

STEM CELLS & REGEN MED

Mary Murphy
STEM CELLS & REGEN MED
14:20

Mechanism of action of MSCs after local injection

Davide Danovi
STEM CELLS & REGEN MED
14:40

Cell characterisation through imaging for cell therapy and drug discovery

Todd C Mcdevitt
STEM CELLS & REGEN MED
15:40

3D scalable suspension culture of stem cells for tissue modelling with increased yield and reduced cost

16:00

Networking refreshments

STEM CELLS & REGEN MED

Stephen Badylak
STEM CELLS & REGEN MED
16:30

The influence of immunomodulatory biomaterials upon stem cell fate

  • The primary determinant of stem cell fate
  • Dynamic reciprocity
  • Endogenous vs. exogenous stem cell therapy
Stephen Badylak, Deputy Director, Mcgowan Institute For Regenerative Medicine, University of Pittsburgh
Marina Tarunina
STEM CELLS & REGEN MED
16:50

Development of Combinatorial Culture Technology for cell and gene therapy applications

  • Combinatorial screening of diverse variables in process development for optimisation of cell and gene therapies.
  • Expansion of hematopoietic stem cells for allogeneic and autologous transplantation.
  • Enhancement of viral transduction efficiency for autologous gene therapy to treat rare diseases.
18:00

Close of conference

last published: 04/Jun/20 09:25